Q
0.296
0.00 (-0.34%)
| Previous Close | 0.297 |
| Open | 0.305 |
| Volume | 12,144 |
| Avg. Volume (3M) | 458,218 |
| Market Cap | 118,624,576 |
| Price / Sales | 0.840 |
| Price / Book | 0.290 |
| 52 Weeks Range |
| Profit Margin | -26.32% |
| Operating Margin (TTM) | -5.41% |
| Diluted EPS (TTM) | -0.200 |
| Quarterly Revenue Growth (YOY) | -56.90% |
| Quarterly Earnings Growth (YOY) | -16.40% |
| Total Debt/Equity (MRQ) | 0.22% |
| Current Ratio (MRQ) | 7.05 |
| Operating Cash Flow (TTM) | 2.96 M |
| Levered Free Cash Flow (TTM) | 3.36 M |
| Return on Assets (TTM) | -3.84% |
| Return on Equity (TTM) | -16.52% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | BGM Group Ltd. | - | - |
AIStockmoo Score
0.3
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | 0.25 |
|
BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 7.29% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Rockefeller Capital Management L.P. | 31 Mar 2026 | 5 |
No data within this time range.
No data within this time range.
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 27 Feb 2023 | - | 06 Mar 2023 | 0.05 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2023 | 0.050 | 1 | 1.30 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |